FDA product code MMW: System, Test, Tumor Marker, Monitoring, Bladder
MMW is the FDA product code for system, test, tumor marker, monitoring, bladder. It is a Class II device, regulated under 21 CFR 866.6010 and reviewed by the Immunology panel. FDA has cleared 9 510(k) submissions under MMW, 1 in the last five years, from 5 different applicants. The average 510(k) review took 251 days (median 120). FDA has posted 1 recall for MMW devices.
Classification
| Field | Value |
|---|---|
| Device name | System, Test, Tumor Marker, Monitoring, Bladder |
| Device class | Class II |
| Regulation | 21 CFR 866.6010 |
| Review panel | IM — Immunology |
| Medical specialty | Immunology |
| Premarket route | 510(k) |
| Third-party 510(k) review eligible | Yes |
510(k) clearances per year for MMW
| Year | Clearances | Avg. review days |
|---|---|---|
| 2023 | 1 | 912 |
Compare with all 510(k) review times · Search every MMW clearance
Top MMW applicants
| Applicant | Clearances | Latest |
|---|---|---|
| Vysis | 3 | 2004-01-22 |
| Bard Diagnostic Sciences,Inc. | 3 | 1998-12-08 |
| Nucleix , Ltd. | 1 | 2023-05-04 |
| Matritech, Inc. | 1 | 2002-07-30 |
| Perimmune, Inc. | 1 | 1997-04-30 |
Most recent MMW clearances
| 510(k) | Applicant | Device | Decision date | Review days |
|---|---|---|---|---|
| K203245 | Nucleix , Ltd. | Bladder EpiCheck DNA extraction kit, NX899090-01C, Bladder EpiCheck test kit, NX899090-02C, Bladder EpiCheck Software, NX899090-03C | 2023-05-04 | 912 |
| K033982 | Vysis | MODIFICATION TO VYSIS UROVYSION BLADDER CANCER RECURRENCE TEST | 2004-01-22 | 30 |
| K021231 | Matritech, Inc. | NMP22 BLADDERCHEK KIT, NMP22 CONTROL KIT | 2002-07-30 | 103 |
| K013785 | Vysis | UROVYSION BLADDER CANCER RECURRENCE KIT | 2002-02-08 | 86 |
| K011031 | Vysis | VYSIS UROVYSION BLADDER CANCER RECURRENCE KIT | 2001-08-03 | 120 |
Recalls for MMW devices
1 product recalls in 1 recall events; 0 initiated in the last five years and 0 still open. Most recent: 2004-02-19.
Frequently asked questions
What is FDA product code MMW?
MMW is the FDA product code for system, test, tumor marker, monitoring, bladder. It is a Class II device, regulated under 21 CFR 866.6010 and reviewed by the Immunology panel.
What device class is MMW?
Class II, regulation 21 CFR 866.6010. Typical premarket route: 510(k).
How long does a 510(k) take for product code MMW?
Across 9 cleared submissions the average was 251 days from receipt to decision (median 120).
Which companies have the most MMW clearances?
Vysis (3); Bard Diagnostic Sciences,Inc. (3); Nucleix , Ltd. (1); Matritech, Inc. (1); Perimmune, Inc. (1).
Have MMW devices been recalled?
Yes: 1 product recalls across 1 recall events; the most recent began 2004-02-19.
Next steps
- Run an FDA pathway report with predicate devices for product code MMW
- Run a recall and safety report across every MMW manufacturer
- Watch product code MMW for new clearances and recalls
Compiled by Caduvo from public U.S. FDA records. Applicant names are shown as FDA records them. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA. Not regulatory advice. Report an error. Data and corrections policy.
All Immunology product codes · FDA product code lookup · 510(k) database search · 510(k) review times